Success Stories: An Irish Doctor in the field of Medicine secures NIW approval in just 19 days, Thanks to the Premium Processing
Client’s Testimonial:
“Chen immigration provided a great service and guidance in relation to my EB2 NIV approval. I initially chose Chen over competitors due to a recommendation from a colleague who was successful in his application using their firm and their competitive pricing. Their method and advice were invaluable to ensuring I set up my application to be approved. I would definitely recommend.”
On May 5th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Doctor from Ireland in the Field of Medicine (Approval Notice).
General Field: Medicine
Position at the Time of Case Filing: Urology Resident
Country of Origin: Ireland
Country of Residence at the Time of Filing: Ireland
Approval Notice Date: May 5th, 2025
Processing Time: 19 days (Premium Processing Requested)
Case Summary:
A doctor from Ireland, advancing critical work in prostate cancer care, combining biomedical engineering and clinical insight to develop predictive models that enhance treatment outcomes, reached out to our law firm for an NIW petition. His proposed endeavor focuses on applying patient-centered analytics to improve decision-making and personalize care for one of America's most commonly diagnosed cancers. His groundbreaking research includes studies on prostatectomy outcomes, robotic surgical techniques, and cancer prognostics. After presenting a compelling case supported by strong credentials and impactful research, his I-140 petition under the EB-2 National Interest Waiver (NIW) category was approved in 19 days under the premium processing.
His research targets one of the most urgent public health challenges in the U.S.
The petitioner’s work directly targets the most urgent public health challenges in the U.S. and addresses this need by using clinical data and AI-based modeling to stratify risk, predict treatment outcomes, and tailor interventions. His methods support earlier diagnoses, better-informed surgical decisions, and ultimately, reduced patient morbidity and mortality.
The petition demonstrated a record of impactful research and scientific recognition. We supported the petition with evidence of the client’s substantial achievements, including:
● A proven expertise in the field of Medicine with a publication record of 31 peer-reviewed journal articles, including 12 first-authored and 1 accepted for publication
● 98 total citations, including multiple references by independent researchers in oncology and surgery
● 11 articles ranked among the most highly cited in Clinical Medicine for their publication years
● 7 verified peer review contributions for respected journals such as BMC Cancer, BMC Urology, and Communications Medicine
● Editorial board membership with BMC Urology, reflecting recognition as a trusted voice in the field
His research has been published in highly ranked journals such as BJU International, International Journal of Molecular Sciences, and Journal of Clinical Medicine, and has been cited by peers investigating prostate cancer diagnostics, radiomics, surgical reconstruction, and targeted therapy outcomes.Two expert recommendation letters supported his case.
The petition included two letters of recommendation, one of which came from an independent U.S.-based scientist. These letters affirmed the originality, innovation, and relevance of his contributions to cancer treatment and clinical research. One recommender wrote:
“[Client] has developed critical insights with regard to cancer care and treatment. His work broadly examines the impact of specific medical techniques on care outcomes, as well as establishing novel biomarkers for complications in surgical interventions. Research such as his is essential to improving planning and delivery of care across healthcare facilities, informing policy development and care guidelines.”
Approval granted in just 19 daysThe USCIS approved the petition just 19 days after filing under the premium processing. We congratulate our client on this swift and well-deserved success and look forward to his continued impact on U.S. public health and cancer care innovation.